361-63-7Relevant articles and documents
Taming of superacids: PVP-triflic acid as an effective solid triflic acid equivalent for Friedel-Crafts hydroxyalkylation and acylation
Prakash, G.K. Surya,Paknia, Farzaneh,Kulkarni, Aditya,Narayanan, Arjun,Wang, Fang,Rasul, Golam,Mathew, Thomas,Olah, George A.
, p. 102 - 112 (2015/03/04)
The application of poly(4-vinylpyridine) supported trifluoromethanesulfonic acid (PVP-TfOH, 1:10) as a convenient solid superacid catalyst system in Friedel-Crafts reactions is described. In the presence of PVP-TfOH, one pot solvent-free synthesis of a wide variety of diarylacetic acid derivatives was achieved by Friedel-Crafts hydroxyalkylation reaction of glyoxylic acid with arenes under mild conditions. Acylation of both activated and deactivated aromatic compounds with acetyl chloride was also achieved using PVP-TfOH complex under solvent-free conditions at room temperature. As the polymer supported triflic acid was found to be a very efficient and an easy-to-handle solid acid, it can be a useful addition to environmentally more adaptable strong acid catalyst systems.
Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors
Tessier, Pierre,Smil, David V.,Wahhab, Amal,Leit, Silvana,Rahil, Jubrail,Li, Zuomei,Deziel, Robert,Besterman, Jeffrey M.
scheme or table, p. 5684 - 5688 (2010/04/30)
We have identified a series of diphenylmethylene hydroxamic acids as novel and selective HDAC class IIa inhibitors. The original hit, N-hydroxy-2,2-diphenylacetamide (6), has sub-micromolar class IIa HDAC inhibitory activity, while the rigidified oxygen a
Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 1. The discovery of arylacetamides as viable replacements for the dihydropyrimidinone moiety of an HTS hit
Jiang, Yu,Chen, Chien-An,Lu, Kai,Daniewska, Irena,De Leon, John,Kong, Ron,Forray, Carlos,Li, Boshan,Hegde, Laxminarayan G.,Wolinsky, Toni D.,Craig, Douglas A.,Wetzel, John M.,Andersen, Kim,Marzabadi, Mohammad R.
, p. 3870 - 3882 (2008/02/09)
Melanin-concentrating hormone (MCH) is involved in the regulation of feeding, water balance, energy metabolism, general arousal and attention state, memory, cognitive functions, and psychiatric disorders. Herein, two new chemical series exemplified by N-[5-(1-{3-[2,2-bis-(4-fluoro-phenyl)-acetylamino]- propyl}-piperidin-4-yl)-2,4-difluoro-phenyl]-isobutyramide (SNAP 102739, 5m) and N-[3-(1-{3-[(S)-2-(4-fluorophenyl)-propionylamino]-propyl}-piperidin-4-yl)-4- methylphenyl]-isobutyramide ((S)-6b) are reported. These compounds were designed to improve the pharmacokinetic properties of the high-throughput screening lead compound 1 (SNAP 7941). The MCH1 receptor antagonists 5m and (S)-6b show reasonable pharmacokinetic profiles (rat bioavailability = 48 and 81%, respectively). Compounds 5m and (S)-6b demonstrated the inhibition of a centrally administered MCH-evoked drinking effect, and compound 5m exhibited oral in vivo efficacy in the rat social interaction model of anxiety, with a minimum effective dose = 0.3 mg/kg.